Results 141 to 150 of about 2,785 (177)
Some of the next articles are maybe not open access.
Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids
Drugs, 2017Oral ulipristal acetate (Esmya®; Fibristal®), a synthetic selective progesterone receptor modulator, is the first selective progesterone modulator to be approved for the treatment of uterine fibroids. It was initially approved for the preoperative treatment of moderate to severe uterine fibroid symptoms in women of reproductive age.
Karly P, Garnock-Jones, Sean T, Duggan
openaire +2 more sources
Endometrial changes during ulipristal acetate use
European journal of obstetrics, gynecology, and reproductive biology, 2017Ulipristal acetate is increasingly used for several clinical indications, like emergency contraception and pre-treatment of uterine fibroids. It has mixed progesterone agonist and antagonist effects in the myometrium and endometrium. Due to its progesterone antagonistic effect, an unopposed estrogen effect could occur which could cause (pre-)malignant ...
De Milliano, Inge +4 more
openaire +1 more source
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly
[Ulipristal acetate, 5mg: a new alternative].
Medicina clinica, 2014Fibroids have a high prevalence (approaching 50%) in the female population. Although they are a benign entity, they represent a health problem of considerable magnitude, causing hemorrhaging, pain and sterility. Surgical treatment is currently safe and effective, but in recent decades numerous less invasive alternatives have appeared, such as uterine ...
Javier, Monleón Sancho +5 more
openaire +1 more source
ULIPRISTAL ACETATE IN UTERINE FIBROIDS
Ulipristal Acetate as alternative to surgery in women with uterine ...openaire +1 more source
Ulipristal Acetate and Pelvic Pain
Journal of Minimally Invasive Gynecology, 2017S.A. Scattolon, A. Bullen, N.A. Leyland
openaire +1 more source
Esmya (ulipristal acetate) - safety update
Drug and Therapeutics Bulletin, 2018openaire +2 more sources